Sunrise Health Medical Associates

Sunrise Health Medical Associates operates as a physician-supervised weight management clinic in Modesto, California, focusing exclusively on GLP-1 receptor agonist therapies for metabolic health and sustainable weight reduction. Under the clinical direction of Dr. Basi, the practice has structured its protocols around two FDA-approved peptide medications—semaglutide and tirzepatide—both administered through individualized treatment plans that account for patient metabolic profiles, comorbid conditions, and weight loss objectives. The clinic serves patients throughout Stanislaus County and the Central Valley region, offering both in-person consultations and follow-up care designed to optimize medication efficacy while minimizing adverse effects.

The semaglutide program at Sunrise Health Medical Associates follows a dose-escalation protocol beginning at 0.25 mg weekly, with adjustments made based on patient tolerance and glycemic response over 16-20 week titration periods. Tirzepatide therapy, which combines GLP-1 and GIP receptor agonism, is initiated at 2.5 mg weekly with similar incremental increases tailored to individual metabolic markers and weight loss velocity. Dr. Basi's approach integrates baseline metabolic panels, hemoglobin A1c monitoring for patients with prediabetes or type 2 diabetes, and regular body composition assessments to track visceral fat reduction alongside total weight changes. Both peptide therapies are prescribed as part of comprehensive programs that include nutritional counseling addressing macronutrient distribution, meal timing strategies that complement GLP-1 pharmacodynamics, and guidance on managing common side effects such as nausea or delayed gastric emptying during the initial treatment phases.

Dr. Basi brings clinical experience in obesity medicine and metabolic disorders to the Modesto practice, emphasizing evidence-based prescribing patterns that align with current American Board of Obesity Medicine guidelines for GLP-1 therapy. The clinic's medical oversight includes pre-treatment screening for contraindications such as personal or family history of medullary thyroid carcinoma, assessment of pancreatic enzyme levels in patients with prior pancreatitis, and careful evaluation of concurrent medications that may interact with incretin-based therapies. Patient consultations address realistic weight loss expectations—typically 15-20% body weight reduction over 12-18 months with semaglutide, and potentially higher percentages with tirzepatide—while discussing the importance of continued lifestyle modifications to maintain metabolic improvements after peptide therapy completion.

Patients beginning treatment at Sunrise Health Medical Associates in Modesto undergo initial consultations that include comprehensive metabolic assessments, discussion of insurance coverage options for GLP-1 medications, and education on proper subcutaneous injection techniques for at-home administration. Follow-up appointments occur every 4-6 weeks during dose titration phases, with extended intervals once therapeutic dosing is achieved and weight loss progresses predictably. The clinic provides ongoing monitoring of cardiovascular risk markers, liver function panels, and kidney function tests, particularly relevant for patients with pre-existing metabolic syndrome or diabetic nephropathy. Dr. Basi's protocols include contingency planning for medication shortages that have periodically affected semaglutide and tirzepatide availability, ensuring patients maintain therapeutic continuity through alternative sourcing or temporary dose adjustments when necessary.

Sunrise Health Medical Associates differentiates its weight management approach through physician availability for medication adjustment decisions, direct communication channels for patients experiencing side effects requiring dose modification, and integration of behavioral health principles that address emotional eating patterns and stress-related weight gain. The Modesto location serves as an accessible option for Central Valley residents seeking medical weight loss without traveling to larger metropolitan areas, with appointment scheduling designed to accommodate working patients through extended weekday hours. The clinic's focus remains narrowly defined around GLP-1 peptide therapy rather than broad wellness services, allowing for specialized expertise in managing the specific challenges and opportunities these medications present for patients with obesity, metabolic dysfunction, or weight-related health complications.